News headlines about Aeglea Bio Therapeutics (NASDAQ:AGLE) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aeglea Bio Therapeutics earned a daily sentiment score of 0.02 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.6251649367828 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Separately, Zacks Investment Research raised shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 target price for the company in a research note on Friday, November 10th.
Shares of Aeglea Bio Therapeutics (NASDAQ AGLE) opened at $5.07 on Tuesday. Aeglea Bio Therapeutics has a 52-week low of $2.81 and a 52-week high of $8.14. The company has a market cap of $84.39 and a PE ratio of -2.77.
In other Aeglea Bio Therapeutics news, CFO Charles N. York II bought 6,500 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were acquired at an average cost of $4.59 per share, for a total transaction of $29,835.00. Following the acquisition, the chief financial officer now directly owns 10,828 shares of the company’s stock, valued at $49,700.52. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Anthony G. Quinn bought 8,288 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The stock was acquired at an average price of $4.96 per share, for a total transaction of $41,108.48. Following the completion of the acquisition, the chief executive officer now directly owns 32,009 shares in the company, valued at $158,764.64. The disclosure for this purchase can be found here. Insiders have acquired a total of 57,691 shares of company stock worth $269,483 over the last 90 days. 27.00% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Aeglea Bio Therapeutics (AGLE) Given News Sentiment Score of 0.02” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/01/09/aeglea-bio-therapeutics-agle-given-news-sentiment-score-of-0-02.html.
About Aeglea Bio Therapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.